Compositions and methods for treating pain in subjects with rheumatoid arthritis
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsSusan Boklage, Toshio Kimura, Stefano Fiore, Gregory St John, Wenhui Wei, Vivian Bykerk
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the use of an anti-IL6 receptor antibody for treating unacceptable pain in subjects with rheumatoid arthritis. Subjects with unacceptable pain can have, e.g., refractory pain or strict refractory pain.
Claims32
A method for treating unacceptable pain (UP) in a subject in need thereof who has rheumatoid arthritis, comprising administration of a therapeutically effective dose of an antibody that specifically binds IL-6 receptor, wherein the antibody comprises a heavy chain variable region comprising complementarity determining regions HCDR1, HCDR2, and HCDR3 and a light chain variable region comprising complementary determining regions LCDR1, LCDR2, and LCDR3, wherein:
- (a) HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 3;
- (b) HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 4;
- (c) HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 5;
- (d) LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 6;
- (e) LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 7;
- and
- (f) LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 8.
(canceled)
(canceled)
(canceled)
(canceled)
13-20. (canceled)
23-29. (canceled)
A method for treating unacceptable pain (UP) in a subject in need thereof, comprising
- (i) selecting a subject who has rheumatoid arthritis and UP;
- and
- (ii) administering to the subject a therapeutically effective dose of an antibody that specifically binds IL-6 receptor, wherein the antibody comprises a heavy chain variable region comprising complementarity determining regions HCDR1, HCDR2, and HCDR3 and a light chain variable region comprising complementary determining regions LCDR1, LCDR2, and LCDR3, wherein:
- (a) HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 3;
- (b) HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 4;
- (c) HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 5;
- (d) LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 6;
- (e) LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 7;
- and
- (f) LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 8.
(canceled)
(canceled)
(canceled)
(canceled)
42-49. (canceled)
52-87. (canceled)
Dependencies are inferred from the claim text.